Overview

Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
A 12-Week, Exploratory, Open-Label, Nonrandomized, Dose-Escalation Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients with Severe, Recalcitrant, Plaque Type Psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
Cephalon